Dennis G. MoledinaSection of Nephrology and Clinical and Translational Research Accelerator, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut;
Mark A. PerazellaSection of Nephrology and Section of Nephrology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut and Veterans Administration Medical Center, West Haven, Connecticut
CortazarFB, KibbelaarZA, GlezermanIG, AbudayyehA, MamloukO, MotwaniSS, et al.: Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: A multicenter study. J Am Soc Nephrol31: 435–446, 2020PubMed
JiaY, SuT, GuY, LiC, ZhouX, SuJ, et al.: HLA-DQA1, -DQB1, and -DRB1 alleles associated with acute tubulointerstitial nephritis in a Chinese population: A single-center cohort study. J Immunol201: 423–431, 2018PubMed
MuriithiAK, NasrSH, LeungN: Utility of urine eosinophils in the diagnosis of acute interstitial nephritis. Clin J Am Soc Nephrol8: 1857–1862, 2013PubMed
MuriithiAK, NasrSH, LeungN: Utility of urine eosinophils in the diagnosis of acute interstitial nephritis. Clin J Am Soc Nephrol 8: 1857–1862, 2013PubMed10.2215/CJN.01330213)| false
GesualdoL, Di PalmaAM, MorroneLF, StrippoliGF, SchenaFP; Italian Immunopathology Group, Italian Society of Nephrology: The Italian experience of the national registry of renal biopsies. Kidney Int66: 890–894, 2004PubMed
GesualdoL, Di PalmaAM, MorroneLF, StrippoliGF, SchenaFP; Italian Immunopathology Group, Italian Society of Nephrology: The Italian experience of the national registry of renal biopsies. Kidney Int 66: 890–894, 2004PubMed10.1111/j.1523-1755.2004.00831.x)| false
MuriithiAK, LeungN, ValeriAM, CornellLD, SethiS, FidlerME, et al.: Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int87: 458–464, 2015PubMed
MuriithiAK, LeungN, ValeriAM, CornellLD, SethiS, FidlerME, : Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int 87: 458–464, 2015PubMed10.1038/ki.2014.294)| false
AntoniouT, MacdonaldEM, HollandsS, GomesT, MamdaniMM, GargAX, et al.: Proton pump inhibitors and the risk of acute kidney injury in older patients: A population-based cohort study. CMAJ Open3: E166–E171, 2015PubMed
AntoniouT, MacdonaldEM, HollandsS, GomesT, MamdaniMM, GargAX, : Proton pump inhibitors and the risk of acute kidney injury in older patients: A population-based cohort study. CMAJ Open 3: E166–E171, 2015PubMed10.9778/cmajo.20140074)| false
QatoDM, WilderJ, SchummLP, GilletV, AlexanderGC: Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med176: 473–482, 2016PubMed
QatoDM, WilderJ, SchummLP, GilletV, AlexanderGC: Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011. JAMA Intern Med 176: 473–482, 2016PubMed10.1001/jamainternmed.2015.8581)| false
LazarusB, ChenY, WilsonFP, SangY, ChangAR, CoreshJ, et al.: Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med176: 238–246, 2016PubMed
LazarusB, ChenY, WilsonFP, SangY, ChangAR, CoreshJ, : Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 176: 238–246, 2016PubMed10.1001/jamainternmed.2015.7193)| false
PengYC, LinCL, YehHZ, ChangCS, WuYL, KaoCH: Association between the use of proton pump inhibitors and the risk of ESRD in renal diseases: A population-based, case-control study. Medicine (Baltimore)95: e3363, 2016PubMed
PengYC, LinCL, YehHZ, ChangCS, WuYL, KaoCH: Association between the use of proton pump inhibitors and the risk of ESRD in renal diseases: A population-based, case-control study. Medicine (Baltimore) 95: e3363, 2016PubMed10.1097/MD.0000000000003363)| false
XieY, BoweB, LiT, XianH, BalasubramanianS, Al-AlyZ: Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol27: 3153–3163, 2016PubMed
AroraP, GuptaA, GolzyM, PatelN, CarterRL, JalalK, et al.: Proton pump inhibitors are associated with increased risk of development of chronic kidney disease. BMC Nephrol17: 112, 2016PubMed
NochaiwongS, RuengornC, AwiphanR, KoyratkosonK, ChaisaiC, NoppakunK, et al.: The association between proton pump inhibitor use and the risk of adverse kidney outcomes: A systematic review and meta-analysis. Nephrol Dial Transplant33: 331–342, 2018PubMed
NochaiwongS, RuengornC, AwiphanR, KoyratkosonK, ChaisaiC, NoppakunK, : The association between proton pump inhibitor use and the risk of adverse kidney outcomes: A systematic review and meta-analysis. Nephrol Dial Transplant 33: 331–342, 2018PubMed10.1093/ndt/gfw470)| false
HelsbyNA, LoWY, SimpsonIJ, VossDM, LoganKE, SearleM, et al.: Omeprazole-induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype. Br J Clin Pharmacol69: 516–519, 2010PubMed
ShiraliAC, PerazellaMA, GettingerS: Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis68: 287–291, 2016PubMed
ShiraliAC, PerazellaMA, GettingerS: Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients. Am J Kidney Dis 68: 287–291, 2016PubMed10.1053/j.ajkd.2016.02.057)| false
SuT, GuY, SunP, TangJ, WangS, LiuG, et al.: Etiology and renal outcomes of acute tubulointerstitial nephritis: A single-center prospective cohort study in China. Nephrol Dial Transplant33: 1180–1188, 2018PubMed
Caravaca-FontánF, ShabakaA, Sánchez-ÁlamoB, de LorenzoA, DíazM, BlascoM, et al.; Spanish Group for the Study of Glomerular Diseases (GLOSEN): Recurrent acute interstitial nephritis: what lies beneath. Clin Kidney J14: 197–204, 2020PubMed
Caravaca-FontánF, ShabakaA, Sánchez-ÁlamoB, de LorenzoA, DíazM, BlascoM, ; Spanish Group for the Study of Glomerular Diseases (GLOSEN): Recurrent acute interstitial nephritis: what lies beneath. Clin Kidney J 14: 197–204, 2020PubMed10.1093/ckj/sfaa018)| false
National Kidney Foundation: Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl2: 19–36, 2012
National Kidney Foundation: Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl 2: 19–36, 2012)| false
PerazellaMA, BombackAS: Urinary eosinophils in AIN: Farewell to an old biomarker?Clin J Am Soc Nephrol 8: 1841–1843, 2013PubMed10.2215/CJN.08620813)| false
MoledinaDG, EadonMT, CalderonF, YamamotoY, ShawM, PerazellaMA, et al.: Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data. Nephrol Dial Transplant346: gfab346, 202110.1093/ndt/gfab346PubMed
MoledinaDG, EadonMT, CalderonF, YamamotoY, ShawM, PerazellaMA, : Development and external validation of a diagnostic model for biopsy-proven acute interstitial nephritis using electronic health record data. Nephrol Dial Transplant 346: gfab346, 202110.1093/ndt/gfab346PubMed10.1093/ndt/gfab346)| false
D’AgatiVD, TheiseND, PiraniCL, KnowlesDM, AppelGB: Interstitial nephritis related to nonsteroidal anti-inflammatory agents and beta-lactam antibiotics: A comparative study of the interstitial infiltrates using monoclonal antibodies. Mod Pathol2: 390–396, 1989PubMed
D’AgatiVD, TheiseND, PiraniCL, KnowlesDM, AppelGB: Interstitial nephritis related to nonsteroidal anti-inflammatory agents and beta-lactam antibiotics: A comparative study of the interstitial infiltrates using monoclonal antibodies. Mod Pathol 2: 390–396, 1989PubMed)| false
ZandL, MonaghanM, GriffinBR, WagnerSJ, CriaciIM, KamalA, et al.: The role of type I hypersensitivity reaction and IgE-mediated mast cell activation in acute interstitial nephritis. Clin Nephrol84: 138–144, 2015PubMed
ZandL, MonaghanM, GriffinBR, WagnerSJ, CriaciIM, KamalA, : The role of type I hypersensitivity reaction and IgE-mediated mast cell activation in acute interstitial nephritis. Clin Nephrol 84: 138–144, 2015PubMed10.5414/CN108254)| false
SpanouZ, KellerM, BritschgiM, YawalkarN, FehrT, NeuweilerJ, et al.: Involvement of drug-specific T cells in acute drug-induced interstitial nephritis. J Am Soc Nephrol17: 2919–2927, 2006PubMed
KorbetSM, GashtiCN, EvansJK, WhittierWL: Risk of percutaneous renal biopsy of native kidneys in the evaluation of acute kidney injury. Clin Kidney J11: 610–615, 2018PubMed
GrahamF, LordM, FromentD, CardinalH, BolléeG: The use of gallium-67 scintigraphy in the diagnosis of acute interstitial nephritis. Clin Kidney J9: 76–81, 2016PubMed
GrahamF, LordM, FromentD, CardinalH, BolléeG: The use of gallium-67 scintigraphy in the diagnosis of acute interstitial nephritis. Clin Kidney J 9: 76–81, 2016PubMed10.1093/ckj/sfv129)| false
MoledinaDG, PerazellaMA: Treatment of drug-induced acute tubulointerstitial nephritis: the search for better evidence. Clin J Am Soc Nephrol13: 1785–1787, 2018PubMed
Fernandez-JuarezG, PerezJV, Caravaca-FontánF, QuintanaL, ShabakaA, RodriguezE, et al.; Spanish Group for the Study of Glomerular Diseases (GLOSEN): Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis. Clin J Am Soc Nephrol13: 1851–1858, 2018PubMed
Fernandez-JuarezG, PerezJV, Caravaca-FontánF, QuintanaL, ShabakaA, RodriguezE, ; Spanish Group for the Study of Glomerular Diseases (GLOSEN): Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis. Clin J Am Soc Nephrol 13: 1851–1858, 2018PubMed10.2215/CJN.01390118)| false
LinJS, MamloukO, SelametU, TchakarovA, GlassWF, ShethRA, et al.: Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. OncoImmunology10: 1877415, 2021PubMed
CamG, KwetcheuAT, VigneauC, SiohanP, QueffeulouG, GataultP, et al.: Acute and chronic nephropathy induced by fluindione must be addressed. Nephrol Dial Transplant27: 1554–1558, 2012PubMed
ParkhieSM, FineDM, LucasGM, AttaMG: Characteristics of patients with HIV and biopsy-proven acute interstitial nephritis. Clin J Am Soc Nephrol5: 798–804, 2010PubMed
ParkhieSM, FineDM, LucasGM, AttaMG: Characteristics of patients with HIV and biopsy-proven acute interstitial nephritis. Clin J Am Soc Nephrol 5: 798–804, 2010PubMed10.2215/CJN.08211109)| false
WendtR, SchlieckerJ, BeigeJ: Inflammatory leucocyte infiltrates are associated with recovery in biopsy-proven acute interstitial nephritis: A 20-year registry-based case series. Clin Kidney J12: 814–820, 2019PubMed
GonzálezE, GutiérrezE, GaleanoC, CheviaC, de SequeraP, BernisC, et al.; Grupo Madrileño De Nefritis Intersticiales: Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int73: 940–946, 2008PubMed
GonzálezE, GutiérrezE, GaleanoC, CheviaC, de SequeraP, BernisC, ; Grupo Madrileño De Nefritis Intersticiales: Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 73: 940–946, 2008PubMed10.1038/sj.ki.5002776)| false
AggarwalKP, NarulaS, KakkarM, TandonC: Nephrolithiasis: molecular mechanism of renal stone formation and the critical role played by modulators. BioMed Res Int2013: 292953, 2013PubMed
AggarwalKP, NarulaS, KakkarM, TandonC: Nephrolithiasis: molecular mechanism of renal stone formation and the critical role played by modulators. BioMed Res Int 2013: 292953, 2013PubMed10.1155/2013/292953)| false
KnaufF, AsplinJR, GranjaI, SchmidtIM, MoeckelGW, DavidRJ, et al.: NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int84: 895–901, 2013PubMed
KnaufF, AsplinJR, GranjaI, SchmidtIM, MoeckelGW, DavidRJ, : NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathy. Kidney Int 84: 895–901, 2013PubMed10.1038/ki.2013.207)| false
Martin-HiguerasC, Ludwig-PortugallI, HoppeB, KurtsC: Targeting kidney inflammation as a new therapy for primary hyperoxaluria?Nephrol Dial Transplant34: 908–914, 2019PubMed
Martin-HiguerasC, Ludwig-PortugallI, HoppeB, KurtsC: Targeting kidney inflammation as a new therapy for primary hyperoxaluria?Nephrol Dial Transplant 34: 908–914, 2019PubMed10.1093/ndt/gfy239)| false
CavanaughC, PerazellaMA: Urine sediment examination in the diagnosis and management of kidney disease: Core curriculum 2019. Am J Kidney Dis73: 258–272, 2019PubMed
CavanaughC, PerazellaMA: Urine sediment examination in the diagnosis and management of kidney disease: Core curriculum 2019. Am J Kidney Dis 73: 258–272, 2019PubMed10.1053/j.ajkd.2018.07.012)| false
GreenMR, ChamberlainMC: Renal dysfunction during and after high-dose methotrexate. Cancer Chemother Pharmacol 63: 599–604, 2009PubMed10.1007/s00280-008-0772-0)| false
Nicholas CosseyL, DvanajscakZ, LarsenCP: A diagnostician’s field guide to crystalline nephropathies. Semin Diagn Pathol 37: 135–142, 2020PubMed10.1053/j.semdp.2020.02.002)| false
MedranoC, ObericL, PuissetF, RecherC, Larrieu-CironD, YsebaertL, et al.: Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients. Leuk Lymphoma62: 846–853, 2021PubMed
MedranoC, ObericL, PuissetF, RecherC, Larrieu-CironD, YsebaertL, : Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients. Leuk Lymphoma 62: 846–853, 2021PubMed10.1080/10428194.2020.1846733)| false
SimonDI, BrosiusFC3rd, RothsteinDM: Sulfadiazine crystalluria revisited. The treatment of toxoplasma encephalitis in patients with acquired immunodeficiency syndrome. Arch Intern Med 150: 2379–2384, 1990PubMed10.1001/archinte.1990.00390220113023)| false
SotoK, CamposP, MansoR, AntunesAMM, MorelloJ, PerazellaMA: Severe acute kidney injury and double tubulopathy due to dual toxicity caused by combination antiretroviral therapy. Kidney Int Rep4: 494–499, 2018PubMed
SotoK, CamposP, MansoR, AntunesAMM, MorelloJ, PerazellaMA: Severe acute kidney injury and double tubulopathy due to dual toxicity caused by combination antiretroviral therapy. Kidney Int Rep 4: 494–499, 2018PubMed10.1016/j.ekir.2018.11.014)| false
SuryK, PerazellaMA: The changing face of human immunodeficiency virus-mediated kidney disease. Adv Chronic Kidney Dis 26: 185–197, 2019PubMed10.1053/j.ackd.2018.12.001)| false
NishijimaT, TsuchiyaK, TanakaN, JoyaA, HamadaY, MizushimaD, et al.: Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3′ untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: A pharmacogenetic study. J Antimicrob Chemother69: 3320–3328, 2014PubMed
NishijimaT, TsuchiyaK, TanakaN, JoyaA, HamadaY, MizushimaD, : Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3′ untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: A pharmacogenetic study. J Antimicrob Chemother 69: 3320–3328, 2014PubMed10.1093/jac/dku304)| false
RosnerMH, JhaveriKD, McMahonBA, PerazellaMA: Onconephrology: The intersections between the kidney and cancer. CA Cancer J Clin 71: 47–77, 2021PubMed10.3322/caac.21636)| false
ZuoC, ZhuY, XuG: An update to the pathogenesis for monoclonal gammopathy of renal significance. Ann Hematol 99: 703–714, 2020PubMed10.1007/s00277-020-03971-1)| false
PerazellaMA, FinkelKW; American Society of Nephrology Onco-Nephology Forum: Paraprotein-related kidney disease: Attack of the killer M proteins. Clin J Am Soc Nephrol11: 2256–2259, 2016PubMed
PerazellaMA, FinkelKW; American Society of Nephrology Onco-Nephology Forum: Paraprotein-related kidney disease: Attack of the killer M proteins. Clin J Am Soc Nephrol 11: 2256–2259, 2016PubMed10.2215/CJN.02960316)| false
LernerG, MoradiS, Cohen-BucayA, ChenH, SanchorawalaV, GordonCE, et al.: Coincidental crystalline light chain cast nephropathy, light chain proximal tubulopathy, and urine crystallopathy: A case report and review of the literature. Clin Nephrol93: 203–208, 2020PubMed
MessiaenT, DeretS, MougenotB, BridouxF, DequiedtP, DionJJ, et al.: Adult Fanconi syndrome secondary to light chain gammopathy: clinicopathologic heterogeneity and unusual features in 11 patients. Medicine (Baltimore)79: 135–154, 2000PubMed
JungM, LeeY, LeeH, MoonKC: Clinicopathological characteristics of light chain proximal tubulopathy in Korean patients and the diagnostic usefulness of immunohistochemical staining for immunoglobulin light chain. BMC Nephrol21: 146, 2020PubMed
JungM, LeeY, LeeH, MoonKC: Clinicopathological characteristics of light chain proximal tubulopathy in Korean patients and the diagnostic usefulness of immunohistochemical staining for immunoglobulin light chain. BMC Nephrol 21: 146, 2020PubMed10.1186/s12882-020-01813-w)| false
StokesMB, ValeriAM, HerlitzL, KhanAM, SiegelDS, MarkowitzGS, et al.: Light chain proximal tubulopathy: Clinical and pathologic characteristics in the modern treatment era. J Am Soc Nephrol27: 1555–1565, 2016PubMed
LeboulleuxM, LelongtB, MougenotB: Protease resistance and binding of Ig light changes in myeloma-associated tubulopathies. Kidney Int 48: 72–79, 1995PubMed10.1038/ki.1995.269)| false
GuptaRK, ArendLJ, BkA, NarsipurS, BhargavaR: Crystalglobulin-associated nephropathy presenting as MGRS in a case of monoclonal B-cell lymphocytosis: A case report. BMC Nephrol21: 184, 2020PubMed
GuptaRK, ArendLJ, BkA, NarsipurS, BhargavaR: Crystalglobulin-associated nephropathy presenting as MGRS in a case of monoclonal B-cell lymphocytosis: A case report. BMC Nephrol 21: 184, 2020PubMed10.1186/s12882-020-01818-5)| false
SunkaraV, PelkowskiTD, DreyfusD, SatoskarA: Acute kidney disease due to excessive vitamin C ingestion and remote Roux-en-Y gastric bypass surgery superimposed on CKD. Am J Kidney Dis66: 721–724, 2015PubMed
SunkaraV, PelkowskiTD, DreyfusD, SatoskarA: Acute kidney disease due to excessive vitamin C ingestion and remote Roux-en-Y gastric bypass surgery superimposed on CKD. Am J Kidney Dis 66: 721–724, 2015PubMed10.1053/j.ajkd.2015.06.021)| false
GettingJE, GregoireJR, PhulA, KastenMJ: Oxalate nephropathy due to ‘juicing’: Case report and review. Am J Med 126: 768–772, 2013PubMed10.1016/j.amjmed.2013.03.019)| false
PfauA, GrujicD, KeddisMT, KauszAT, LieskeJC, KnaufF: Pilot study of reloxaliase in patients with severe enteric hyperoxaluria and hyperoxalemia. Nephrol Dial Transplant36: 945–948, 2021PubMed
PfauA, GrujicD, KeddisMT, KauszAT, LieskeJC, KnaufF: Pilot study of reloxaliase in patients with severe enteric hyperoxaluria and hyperoxalemia. Nephrol Dial Transplant 36: 945–948, 2021PubMed10.1093/ndt/gfaa379)| false
LiebowA, LiX, RacieT, HettingerJ, BettencourtBR, NajafianN, et al.: An investigational RNAi therapeutic targeting glycolate oxidase reduces oxalate production in models of primary hyperoxaluria. J Am Soc Nephrol28: 494–503, 2017PubMed
GarrelfsSF, FrishbergY, HultonSA, KorenMJ, O’RiordanWD, CochatP, et al.; ILLUMINATE-A Collaborators: Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1. N Engl J Med384: 1216–1226, 2021PubMed
WyattCM, DrüekeTB: Stiripentol for the treatment of primary hyperoxaluria and calcium oxalate nephropathy. Kidney Int 97: 17–19, 2020PubMed10.1016/j.kint.2019.06.011)| false
BeallDP, HensleeHB, WebbHR, ScofieldRH: Milk-alkali syndrome: A historical review and description of the modern version of the syndrome. Am J Med Sci331: 233–242, 2006PubMed
BeallDP, HensleeHB, WebbHR, ScofieldRH: Milk-alkali syndrome: A historical review and description of the modern version of the syndrome. Am J Med Sci 331: 233–242, 2006PubMed10.1097/00000441-200605000-00001)| false
Matuszkiewicz-RowinskaJ, MalyszkoJ: Prevention and treatment of tumor lysis syndrome in the era of onco-nephrology progress. Kidney Blood Press Res45: 645–660, 2020PubMed
Matuszkiewicz-RowinskaJ, MalyszkoJ: Prevention and treatment of tumor lysis syndrome in the era of onco-nephrology progress. Kidney Blood Press Res 45: 645–660, 2020PubMed10.1159/000509934)| false
van BerkelY, LudwigM, van WijkJAE, BökenkampA: Proteinuria in Dent disease: A review of the literature. Pediatr Nephrol 32: 1851–1859, 2017PubMed10.1007/s00467-016-3499-x)| false
DicksonFJ, SayerJA: Nephrocalcinosis: a review of monogenic causes and insights they provide into this heterogeneous condition. Int J Mol Sci21: 369, 2020PubMed
DicksonFJ, SayerJA: Nephrocalcinosis: a review of monogenic causes and insights they provide into this heterogeneous condition. Int J Mol Sci 21: 369, 2020PubMed10.3390/ijms21010369)| false
Tesser PoloniJA, PerazellaMA: A rarely recognized cause of acute kidney injury in rhabdomyolysis. Am J Med Sci 356: e27, 2018PubMed10.1016/j.amjms.2017.03.028)| false
BardinT, NguyenQD, TranKM, LeNH, DoMD, RichetteP, et al.: A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. Kidney Int99: 218–226, 2021PubMed
BardinT, NguyenQD, TranKM, LeNH, DoMD, RichetteP, : A cross-sectional study of 502 patients found a diffuse hyperechoic kidney medulla pattern in patients with severe gout. Kidney Int 99: 218–226, 2021PubMed10.1016/j.kint.2020.08.024)| false
SellmayrM, Hernandez PetzscheMR, MaQ, KrügerN, LiapisH, BrinkA, et al.: Only hyperuricemia with crystalluria, but not asymptomatic hyperuricemia, drives progression of chronic kidney disease. J Am Soc Nephrol31: 2773–2792, 2020PubMed
SellmayrM, Hernandez PetzscheMR, MaQ, KrügerN, LiapisH, BrinkA, : Only hyperuricemia with crystalluria, but not asymptomatic hyperuricemia, drives progression of chronic kidney disease. J Am Soc Nephrol 31: 2773–2792, 2020PubMed10.1681/ASN.2020040523)| false
SasDJ, HarrisPC, MillinerDS: Recent advances in the identification and management of inherited hyperoxalurias. Urolithiasis 47: 79–89, 2019PubMed10.1007/s00240-018-1093-3)| false
VeysKRP, ElmonemMA, Van DyckM, JanssenMC, CornelissenEAM, HohenfellnerK, et al.: Chitotriosidase as a novel biomarker for therapeutic monitoring of nephropathic cystinosis. J Am Soc Nephrol31: 1092–1106, 2020PubMed
VeysKRP, ElmonemMA, Van DyckM, JanssenMC, CornelissenEAM, HohenfellnerK, : Chitotriosidase as a novel biomarker for therapeutic monitoring of nephropathic cystinosis. J Am Soc Nephrol 31: 1092–1106, 2020PubMed10.1681/ASN.2019080774)| false
NasrSH, SethiS, CornellLD, MillinerDS, BoelkinsM, BroviacJ, et al.: Crystalline nephropathy due to 2,8-dihydroxyadeninuria: An under-recognized cause of irreversible renal failure. Nephrol Dial Transplant25: 1909–1915, 2010PubMed
